The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.
 
Hai-Qiang Mai
No Relationships to Disclose
 
Sai Lan Liu
No Relationships to Disclose
 
Qiu-Yan Chen
No Relationships to Disclose
 
Lin-Quan Tang
No Relationships to Disclose
 
Feng Jin
No Relationships to Disclose
 
Ling Guo
No Relationships to Disclose
 
Haiqing Luo
No Relationships to Disclose
 
Ying Hu
No Relationships to Disclose
 
Huai Liu
No Relationships to Disclose
 
Jin-Hui Liang
No Relationships to Disclose
 
Chong Zhao
No Relationships to Disclose
 
Dong-Hua Luo
No Relationships to Disclose
 
Hao-Yuan Mo
No Relationships to Disclose
 
Shan-Shan Guo
No Relationships to Disclose
 
Li-Ting Liu
No Relationships to Disclose
 
Ji-Bin Li
No Relationships to Disclose
 
Lin Wang
No Relationships to Disclose
 
Xue-Song Sun
No Relationships to Disclose
 
Xiao-Yun Li
No Relationships to Disclose
 
Pan Wang
No Relationships to Disclose